Pharmacology, Toxicology and Pharmaceutical Science
Prospective Cohort Study
100%
All Cause Mortality
95%
Chronic Kidney Failure
92%
Cardiovascular Disease
71%
Hemodialysis
47%
Cohort Study
42%
Infection
29%
Vitamin D
27%
Vitamin D Receptor
26%
Kidney Disease
25%
Remission
24%
Renin
22%
Angiotensin
22%
Observational Study
21%
Secondary Hyperparathyroidism
20%
Recombinant Erythropoietin
20%
Continuous Erythropoiesis Receptor Activator
19%
ANCA Associated Vasculitis
19%
Randomized Clinical Trial
19%
Ischemic Heart Disease
19%
Mortality Rate
17%
Adverse Event
16%
Survival Rate
14%
Renin-Angiotensin System Inhibitor
14%
Neutrophil Cytoplasmic Antibody
14%
Parathyroid Hormone
14%
Cause of Death
13%
Antianemic Agent
13%
Combination Therapy
13%
End Stage Renal Disease
13%
Disease
12%
Angiotensin Receptor Antagonist
12%
Alfacalcidol
12%
Proteinuria
11%
Phosphate Binding Agent
11%
Vasculitis
11%
Human Study
11%
Nephrosclerosis
11%
Congestive Heart Failure
11%
High Density Lipoprotein Cholesterol
10%
Serum Albumin
9%
Dicarbonate
9%
Glomerulonephritis
9%
Microangiopathy
9%
Arteriovenous Fistula
9%
Ferrous Sulfate
9%
Hyperuricemia
9%
Antihypertensive Agent
9%
Brain Natriuretic Peptide
9%
Alkaline Phosphatase
9%
Medicine and Dentistry
Chronic Kidney Disease
86%
All Cause Mortality
63%
Prospective Cohort Study
55%
Cardiovascular System
48%
Kidney Function
48%
Glomerular Filtration Rate
47%
End Stage Renal Disease
33%
Vascular Access
28%
Retrospective Cohort Study
28%
Cohort Analysis
28%
Nephrology
25%
Hemodialysis
25%
Hazard Ratio
24%
Proteinuria
24%
Isotopes of Calcium
22%
Nephropathy
22%
Phosphate Binder
21%
Cardiovascular Disease
20%
Vitamin D Receptor
20%
Lipoprotein Apheresis
19%
ANCA Associated Vasculitis
19%
Aortic Valve Stenosis
19%
Analeptic
19%
Erythropoietin
19%
Proportional Hazards Model
18%
Creatinine
17%
Hematinic
15%
Observational Study
15%
Neutrophil Cytoplasmic Antibody
14%
Serum Albumin
13%
Fibroblast Growth Factor 23
13%
Urinary System
13%
Mortality Rate
12%
Vasculitis
12%
Prevalence
12%
Renal Biopsy
12%
Myeloperoxidase
12%
Outpatient
12%
Infection
11%
Odds Ratio
11%
Congestive Heart Failure
11%
Cancer
11%
Combination Therapy
11%
Population
11%
Sodium Bicarbonate
11%
Recombinant Erythropoietin
10%
Malignant Neoplasm
10%
Human Study
10%
Acute Kidney Injury
10%
Prospective Study
10%
Keyphrases
Dialysis Initiation
54%
Multicenter Cohort Study
32%
Prospective Cohort Study
31%
Incident Dialysis Patients
28%
Confidence Interval
26%
Dialysis
25%
All-cause Mortality
23%
Hazard Ratio
21%
Dialysis Efficiency
21%
Japanese Patients
21%
Stage 5 Chronic Kidney Disease
19%
Malignancy
19%
Antineutrophil Cytoplasmic Antibody-associated Vasculitis
19%
Retrospective Cohort Study
19%
Chronic Kidney Disease
17%
Remission
16%
End-stage Kidney Disease
14%
Renin-angiotensin System Inhibitors
14%
ANCA-associated Vasculitis
14%
Infection-related Mortality
14%
MPO-ANCA
12%
Angiotensin Receptor Blockers
12%
Cardiovascular Disease
12%
Non-dialysis
12%
Cardiovascular Events
11%
PTH Level
10%
Clinical Outcomes
10%
Vitamin D Receptor Activator
10%
Subgroup Analysis
10%
Minimal Change Disease
9%
Remission of Proteinuria
9%
Adult Patients
9%
Darbepoetin Alfa
9%
Mass Quality
9%
Hemoglobin Level
9%
Outcome Analysis
9%
Sex Differences
9%
Phosphorus Levels
9%
Thrombotic Microangiopathy
9%
Vascular Access
9%
Ferrous Sulfate
9%
Ferric Citrate
9%
Hyperuricemia
9%
Evolocumab
9%
Maxacalcitol
9%
Parathyroid Glands
9%
Epoetin Alfa
9%
Maintenance Hemodialysis Patients
9%
Renal Anemia
9%
Baseline Trend
9%